Ph.D. Program in Biomedical Sciences and Oncology

Bironzo P, Mele T, Novello S. Achievements in targeted therapies. Eur Respir Monogr 2015; 68: 215-233

Rondon-Lagos M, Verdun Di Cantogno L, Rangel N, Mele T, Ramirez-Clavijo SR, Scagliotti GV, Marchiò C, Sapino A. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. BMC Cancer. 2014 Dec 7;14:922. doi: 10.1186/1471-2407-14-922.

Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. Extending Survival of Stage IV Non-Small Cell Lung Cancer Semin Oncol. 2014 Feb;41(1):69-92. doi: 10.1053/j.seminoncol.2013.12.013.

Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Res. 2011 Feb 3;13(1):R16. doi: 10.1186/bcr2825.

Berruti A, Generali D, Bertaglia V, Brizzi MP, Mele T, Dogliotti L, Bruzzi P, Bottini A. Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients J Natl Cancer Inst Monogr. 2011;2011(43):142-6. doi: 10.1093/jncimonographs/lgr036.

Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Res Treat. 2010 Oct; 123(3): 795-804